PT-141 (Bremelanotide): Reported Timelines in the Literature

PT-141, formally bremelanotide (also written BMT, and marketed in some jurisdictions as Vyleesi), is a synthetic cyclic heptapeptide and a melanocortin receptor agonist. It is supplied as bremelanotide acetate, a salt form whose stability and degradation behaviour have been characterised by LC-HRMS/MS alongside computational modelling of epimerisation [9]. The compound is a macrocyclic peptide, a modality that has been described as occupying a "Goldilocks" position between small molecules and biologics in terms of affinity, stability and pharmacokinetic behaviour [1]. Bremelanotide is one of two macrocyclic peptides whose recent clinical progress is cited as evidence for that positioning, the other being setmelanotide [1].

The work on this compound centres on the melanocortin receptor family, with MC4R activation being the mechanism most directly examined in the registered human studies described below [8].

Research Studies

PT-141 (Bremelanotide) and melanocortin receptor selectivity in macrocycle design

Bremelanotide appears in the literature both as a subject of study and as a reference point for analogue design. A series of 14 macrocyclic peptide analogues with 19- to 23-membered rings was designed and synthesised from the MT-II, SHU-9119 and PG-901 scaffolds, and their pharmacological activities were assessed against human MC1R, MC3R, MC4R and MC5R [1]. The stated motivation was the difficulty of achieving selective melanocortin receptor targeting with optimal pharmacological profiles, a problem the authors frame against the clinical progress of bremelanotide and setmelatotide as macrocyclic peptides [1]. This is in vitro receptor pharmacology; it does not establish any timeline in a living system.

PT-141 (Bremelanotide) and MC4R activation in premenopausal women with HSDD

One registered study was designed specifically to evaluate the effects of MC4R activation on brain activity patterns and behavioural psychometric measures of sexual arousal during visual erotic stimuli. The design was a randomised, double-blind, placebo-controlled, two-way crossover physiological study in approximately 40 right-handed, heterosexual, premenopausal women aged 18 years and over with hypoactive sexual desire disorder of at least six months' duration [8]. Because the design is a crossover physiological study rather than a longitudinal trial, the time-related information it yields concerns the interval between administration and the measurement of arousal-related outcomes, not long-term change.

PT-141 (Bremelanotide) and subcutaneous administration in premenopausal women with HSDD

A separate Phase 3 bridging trial was designed to evaluate the efficacy and safety of subcutaneously administered bremelanotide in premenopausal women with hypoactive sexual desire disorder, with or without decreased arousal. The design was multicentre, randomised, double-blind, placebo-controlled and parallel-group [7]. The parallel-group structure is relevant to any timeline question, because participants are followed within a single treatment arm rather than crossing between conditions.

PT-141 (Bremelanotide) and the HSDD clinical trial landscape

A systematic review of completed studies registered on ClinicalTrials.gov examined emerging pharmacological therapies for hypoactive sexual desire disorder in adult women. The review's background notes that HSDD is prevalent and distressing, that pharmacological options remain limited, and that evidence from individual trials is heterogeneous, which the authors give as the rationale for a systematic evaluation of registered trials, their efficacy endpoints and safety profiles [2]. Bremelanotide sits within that body of registered trial evidence. The review is a synthesis of trial records; it does not itself generate new timeline data.

PT-141 (Bremelanotide) and breast milk pharmacokinetics in lactating women

An open-label pharmacokinetic study was designed to evaluate whether bremelanotide is secreted in breast milk in lactating women treated with a single 1.75 mg subcutaneous dose, and to measure the concentration and characterise the pharmacokinetics of any bremelanotide secreted into breast milk. The study was planned in 10 healthy lactating female subjects between 10 days and 6 months post-partum inclusive, with a maximum participation duration of approximately 29 days comprising a 3-week screening period and a 1-day treatment period [4]. This is the most explicitly time-structured of the registered studies described here, because its primary objectives are concentration measurement and pharmacokinetic characterisation.

PT-141 (Bremelanotide) co-administered with tirzepatide in obesity

A Phase 2 study was designed to evaluate the co-administration of bremelanotide with tirzepatide for the treatment of obesity. The design was prospective, randomised, double-blind and placebo-controlled, in subjects with a BMI from 30.0 to 45.0 kg/m2 inclusive [5]. The combination design means any reported timeline would pertain to the co-administered regimen rather than to bremelanotide alone.

PT-141 (Bremelanotide) in diabetic kidney disease

A Phase IIb, multicentre, open-label, prospective study was designed to assess the efficacy of bremelanotide when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects were to remain in the trial for further assessment and to undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months [6]. The six-month and 12-month assessment points are stated in the registered design.

PT-141 (Bremelanotide) as a peptide therapeutic in ageing research

A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base and safety profiles of peptides with demonstrated or potential applications in healthy ageing and age-related conditions, drawing on searches of PubMed, Scopus and the FDA and WADA regulatory databases from inception through January 2026 [3]. The review situates peptide therapeutics against hallmarks of ageing including metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline [3]. Bremelanotide is a peptide therapeutic within the scope of such reviews; the review itself is not a source of compound-specific timeline data.

PT-141 (Bremelanotide) and D-amino acid chemistry in approved drugs

A historical and developmental review of FDA-approved drugs containing D-amino acids describes D-amino acids as non-natural enantiomers of L-amino acids that confer resistance to proteolytic degradation, enhanced conformational rigidity and reduced immunogenicity, properties the authors identify as valuable in long-acting peptide design [11]. This is a chemistry and drug-development review; it does not report administration-to-effect intervals for any individual compound.

Comparison of registered study designs

If you are reading this for personal health reasons

The material described here is sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for their own use should speak to a licensed clinician.

Sources

• [1] Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors — https://europepmc.org/article/PMC/PMC13492293
• [2] Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women — https://europepmc.org/article/PMC/PMC13237691
• [3] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
• [4] Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk — https://clinicaltrials.gov/study/NCT06867835
• [5] A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity — https://clinicaltrials.gov/study/NCT06565611
• [6] A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease — https://clinicaltrials.gov/study/NCT05709444
• [7] A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder — https://clinicaltrials.gov/study/NCT04943068
• [8] Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder — https://clinicaltrials.gov/study/NCT04179734
• [9] Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling — https://pubmed.ncbi.nlm.nih.gov/42485063/
• [10] Quantification of "Mercy Sex" in Heterosexual Women — https://pubmed.ncbi.nlm.nih.gov/42144994/
• [11] FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective — https://pubmed.ncbi.nlm.nih.gov/42041173/
• [12] Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men? — https://pubmed.ncbi.nlm.nih.gov/41960633/